Checkit plc (AIM: CKT) is pleased to announce it has signed a three year contract with Biomat USA, Inc., a subsidiary of Grifols S.A. (“Grifols”). The contract has a minimum total value of £2.8 million spread evenly over the three year period, and will involve providing services to over 300 sites which will see Checkit extend its US footprint within Grifols to initially five of its US subsidiaries.
Grifols is a global leader in the production of plasma-derived medicine and transfusion medicines. Headquartered in Spain, it has a worldwide network of over 350 plasma centres, including more than 50 in Europe. With revenues of €5.3bn (of which €3.6bn were generated from US operations during 2020), Grifols employs 24,000 people providing products and services in more than 100 countries worldwide.
Of the total contract value, approximately 12% represents the renewal of existing business with Grifols with the remainder representing upsell and new business.
The agreement establishes Checkit as Grifols’ partner of choice for the provision of intelligent operations technology in the US. In addition, expansion of the Checkit platform to cover Grifols’ key countries of operations in Europe is at advanced stages of discussion.
Additionally, Grifols plans to build 20 plasma centres in Egypt, with Checkit having recently signed a separate three year contract to provide intelligent operations services to the first ten of these.
Checkit CEO Kit Kyte said: “We look forward to the continued growth of our relationship internationally. Our partners at Grifols already appreciate the power of our monitoring services and the future addition of workflow management will give them unprecedented levels of digital control and data-driven insight, as we look for ways to streamline their complex, globally distributed operations. This deal provides further confirmation of the importance of our technology in enabling intelligent operations across deskless workforces.”